Immunoprecise Antibodies Ltd (NASDAQ:IPA) — Market Cap & Net Worth
Market Cap & Net Worth: Immunoprecise Antibodies Ltd (IPA)
Immunoprecise Antibodies Ltd (NASDAQ:IPA) has a market capitalization of $95.54 Million ($95.54 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19439 globally and #4402 in its home market, demonstrating a -25.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunoprecise Antibodies Ltd's stock price $2.07 by its total outstanding shares 46154100 (46.15 Million). Review IPA total debt and obligations to assess the company's total debt and financial obligations.
Immunoprecise Antibodies Ltd Market Cap History: 2015 to 2025
Immunoprecise Antibodies Ltd's market capitalization history from 2015 to 2025. Data shows growth from $692.31K to $95.54 Million (20.99% CAGR).
Index Memberships
Immunoprecise Antibodies Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #549 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1886 of 3165 |
Weight: Immunoprecise Antibodies Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunoprecise Antibodies Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunoprecise Antibodies Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.90x
Immunoprecise Antibodies Ltd's market cap is 3.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $230.77K | $1.90 Million | $151.03K | 0.12x | 1.53x |
| 2017 | $107.77 Million | $2.63 Million | -$5.38 Million | 40.96x | N/A |
| 2018 | $117.92 Million | $5.44 Million | -$5.17 Million | 21.67x | N/A |
| 2019 | $101.54 Million | $10.93 Million | -$7.62 Million | 9.29x | N/A |
| 2020 | $690.00 Million | $14.06 Million | -$4.95 Million | 49.08x | N/A |
| 2021 | $247.39 Million | $17.91 Million | -$7.34 Million | 13.81x | N/A |
| 2022 | $240.46 Million | $19.36 Million | -$16.71 Million | 12.42x | N/A |
| 2023 | $78.92 Million | $20.66 Million | -$26.56 Million | 3.82x | N/A |
| 2024 | $19.00 Million | $24.52 Million | -$27.18 Million | 0.78x | N/A |
| 2025 | $95.54 Million | $24.52 Million | -$30.23 Million | 3.90x | N/A |
Competitor Companies of IPA by Market Capitalization
Companies near Immunoprecise Antibodies Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Immunoprecise Antibodies Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Immunoprecise Antibodies Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Immunoprecise Antibodies Ltd's market cap moved from $692.31K to $ 95.54 Million, with a yearly change of 20.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $95.54 Million | +402.79% |
| 2024 | $19.00 Million | -75.92% |
| 2023 | $78.92 Million | -67.18% |
| 2022 | $240.46 Million | -2.80% |
| 2021 | $247.39 Million | -64.15% |
| 2020 | $690.00 Million | +579.55% |
| 2019 | $101.54 Million | -13.89% |
| 2018 | $117.92 Million | +9.42% |
| 2017 | $107.77 Million | +46600.00% |
| 2016 | $230.77K | -66.67% |
| 2015 | $692.31K | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Immunoprecise Antibodies Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $95.54 Million USD |
| MoneyControl | $95.54 Million USD |
| MarketWatch | $95.54 Million USD |
| marketcap.company | $95.54 Million USD |
| Reuters | $95.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in … Read more